Table 2.
Association between stress hyperglycemia ratio (SHR) and hemoglobin-to-red blood cell distribution width ratio (HB/RDW) and stroke outcomes (n=345)
| Outcomes | High SHR (≥1.18) -- low HB/RDW (≤0.76) | |||
|---|---|---|---|---|
| No--No (n= 180) | No--Yes (n=53) | Yes--No (n=75) | Yes--Yes (n=37) | |
| In-hospital mortality | ||||
| N (%) | 9 (5.00) | 11 (20.75) | 23 (30.67) | 22 (59.46) |
| AAR | 0.06(0.02, 0.09) | 0.17(0.08, 0.25) | 0.30(0.20, 0.40) | 0.53(0.39, 0.68) |
| ARR | 1.00(Reference) | 2.93(1.29, 6.63) | 5.27(2.55, 10.89) | 9.42(4.70, 18.90) |
| P | NA | 0.010 | <0.001 | <0.001 |
| In-hospital poor functional outcome (mRS ≥3) | ||||
| N (%) | 94 (52.22) | 31 (58.49) | 58 (77.33) | 30 (81.08) |
| AAR | 0.54(0.47, 0.62) | 0.53(0.41, 0.65) | 0.77(0.67, 0.86) | 0.78(0.65, 0.92) |
| ARR | 1.00(Reference) | 0.97(0.74, 1.27) | 1.41(1.17, 1.69) | 1.44(1.15, 1.79) |
| P | NA | 0.842 | <0.001 | <0.001 |
| In-hospital Early neurological deterioration † | ||||
| N (%) | 20 (11.11) | 6 (11.32) | 20 (26.67) | 12 (34.43) |
| AAR | 0.12(0.07, 0.16) | 0.11(0.02, 0.19) | 0.26(0.16, 0.36) | 0.31(0.16, 0.46) |
| ARR | 1.00(Reference) | 0.91(0.36, 2.27) | 2.21(1.25, 3.92) | 2.68(1.40, 5.14) |
| P | NA | 0.834 | 0.006 | 0.003 |
| 3-month all-cause mortality ‡ | ||||
| N (%) | 15 (8.33) | 13 (24.53) | 32 (42.67) | 24 (64.86) |
| AAR | 0.09(0.05, 0.14) | 0.20(0.11, 0.28) | 0.43(0.31, 0.54) | 0.55(0.39, 0.70) |
| ARR | 1.00(Reference) | 2.09(1.08, 4.06) | 4.57(2.62, 7.98) | 5.84(3.27, 10.42) |
| P | NA | 0.029 | <0.001 | <0.001 |
| 3-month poor functional outcome (mRS ≥3) | ||||
| N (%) | 39 (21.67) | 22 (41.51) | 54 (72.00) | 29 (78.38) |
| AAR | 0.23(0.17, 0.30) | 0.36(0.24, 0.47) | 0.72(0.62, 0.83) | 0.68(0.54, 0.82) |
| ARR | 1.00(Reference) | 1.52(0.99, 2.33) | 3.09(2.26, 4.21) | 2.91(2.05, 4.15) |
| P | NA | 0.054 | <0.001 | <0.001 |
| 3-month excellent functional outcome (mRS 0-1) | ||||
| N (%) | 112 (62.22) | 29 (54.72) | 19 (25.33) | 5 (13.51) |
| AAR | 0.59(0.52, 0.65) | 0.61(0.47, 0.76) | 0.26(0.16, 0.36) | 0.15(0.03, 0.27) |
| ARR | 1.00(Reference) | 1.04(0.80, 1.36) | 0.44(0.30, 0.66) | 0.26(0.12, 0.58) |
| P | NA | 0.745 | <0.001 | 0.001 |
| 3- month functional independence (mRS 0-2) | ||||
| N (%) | 141 (78.33) | 31 (58.49) | 21 (28.00) | 8 (21.62) |
| AAR | 0.74(0.68, 0.80) | 0.66(0.53, 0.80) | 0.28(0.18, 0.38) | 0.25(0.10, 0.40) |
| ARR | 1.00(Reference) | 0.90(0.72, 1.12) | 0.38(0.26, 0.54) | 0.34(0.18, 0.62) |
| P | NA | 0.348 | <0.001 | <0.001 |
Data are presented with 95% confidence interval. †Early neurological deterioration was characterized by an increase of ≥2 points in the NIHSS score between baseline and the 72-hour evaluation. ‡All-cause mortality at the 3-month follow-up was derived from a combination of in-hospital mortality and post-discharge mortality. Adjusting factors: age, sex, prior stroke, preexisting dependency, atrial fibrillation, myocardial infarction, congestive heart failure, chronic kidney disease, and history of malignancy. AAR; adjusted absolute risk; ARR: adjusted relative risk; mRS: modified Rankin Scale; NA: not available.